Learn how tirzepatide works as a dual GIP/GLP-1 receptor agonist, its powerful effects on blood sugar, weight loss, and metabolic health, and why it’s transforming obesity and type 2 diabetes treatment.
Discover how AI and machine learning are revolutionizing pharmacovigilance, from intelligent case intake and triage to signal detection and workflow automation, helping drug safety teams manage growing data volumes while staying compliant and patient-focused.
Discover how AI and machine learning are transforming small molecule drug discovery—from high-throughput screening and chemical intuition to data-driven generative models that design clinically viable candidates in record time.
Discover how tirzepatide, a dual GIP and GLP‑1 receptor agonist, transforms type 2 diabetes treatment by enhancing glucose‑dependent insulin secretion, reducing glucagon, slowing gastric emptying, and promoting significant weight loss.
Learn what lerodalcibep is, how this next-generation PCSK9 inhibitor works, and why its once-monthly dosing and potent LDL-C reduction could transform dyslipidemia and ASCVD management in 2025 and beyond.
Discover how artificial intelligence and machine learning are reshaping pharmacovigilance, from automated case processing to intelligent signal detection, enabling faster, more consistent drug safety monitoring across the product lifecycle.
Learn how molecular glue small molecules rewire protein–protein interactions, enable targeted protein degradation, and unlock “undruggable” targets in oncology, neurology, and immunology. Explore their mechanism, history from thalidomide to rational design, and role in AI-driven drug discovery.
Discover how AI-driven pharmacovigilance is transforming drug safety by leveraging social media, wearables, electronic health records, and real-world evidence to detect adverse drug reactions earlier and enable proactive risk management.
Learn what cenobamate is, how its dual mechanism targets sodium channels and GABA receptors, and why neurologists are excited about its seizure‑reduction results in adults with drug‑resistant focal epilepsy.
Discover how tirzepatide, a dual GIP and GLP‑1 receptor agonist, is redefining metabolic medicine with powerful HbA1c reductions and unprecedented weight loss results in obesity and type 2 diabetes clinical trials.